PARP1 and neoplasm: The authors suggested that further studies are required to establish the consequences of PARP blockade both in terms of overall impact on CD4+ T cell infiltration at the tumor site and of the role of different CD4+ T cell subgroups in the antitumor efficacy of PARPi.